New York City health officials confirmed the first case of severe mpox clade I in a city resident who recently traveled internationally, marking a significant development in tracking the more dangerous strain of the virus formerly known as monkeypox.

Understanding the Threat

The NYC Health Department identified mpox clade I in one resident, a strain that causes substantially more severe symptoms than the version that spread globally in 2022. Dr. Marc Siegel, Fox News senior medical analyst, explained that clade I can be life-threatening and spreads through direct contact, sexual activity, kissing, and close respiratory droplets. Unlike common airborne illnesses, it does not transmit over longer distances through respiratory spread, requiring intimate contact for transmission.

The 2022 outbreak involved clade II, which carried a survival rate exceeding 99.9 percent. Clade I, responsible for the 2024 outbreak in the Democratic Republic of Congo and across Africa, produces more severe illness and higher death rates. NYC Health Commissioner Dr. Alister Martin assured residents that no local transmission has occurred and the risk to New Yorkers remains low since the case appears linked to international travel.

Vaccination and Prevention Measures

Health officials recommend the two-dose JYNNEOS vaccine series for New Yorkers at elevated risk. The Centers for Disease Control and Prevention specifically advises vaccination for men who are gay, bisexual, or have sex with men, are 18 or older, and face other specific risk factors. Anyone planning travel to regions where clade I mpox is spreading should also seek vaccination. People potentially exposed through close contact with infected individuals should receive the vaccine within 14 days. Those who previously contracted mpox do not require vaccination.

Symptoms and Treatment

Mpox symptoms typically emerge one to three weeks after exposure and include painful blister-like rashes on various body parts, fever, chills, exhaustion, muscle aches, headache, swollen lymph nodes, and respiratory symptoms. Rare complications include eye infections, severe rashes, painful skin lesions, and neurological problems. Immunocompromised individuals and very young children face the greatest risk of severe infection. Treatment primarily involves supportive care to manage symptoms, though severe cases may receive TPOXX, an antiviral medication designed to treat infections from viruses related to smallpox. Vaccination reduces infection chances and lessens symptom severity when breakthrough infections occur.